Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Hengrui Pharmaceuticals Secures Third NMPA Approval for Trastuzumab Rezetecan in HER2-Positive Colorectal Cancer

Fineline Cube Aug 7, 2026
Company Drug

TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations

Fineline Cube Aug 7, 2026
Company Deals

Eisai and GE Healthcare Sign MoU at CIIE to Collaborate on Alzheimer’s Disease Solutions

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), Japan-based Eisai Co., Ltd (TYO: 4523) entered...

Company Deals

Lohmann & Rauscher Partners with Allmed Medical Products at CIIE for Medical Dressings

Fineline Cube Nov 7, 2024

Lohmann & Rauscher, a medical group with headquarters in Germany and Austria, has entered into...

Company

I-Mab Appoints Sean (Xi-Yong) Fu as Permanent CEO, Effective November 1, 2024

Fineline Cube Nov 7, 2024

US-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has announced the appointment of Sean (Xi-Yong) Fu, PhD,...

Company

Novo Nordisk Reports Q3 2024 Financials with 24% YOY Revenue Growth

Fineline Cube Nov 7, 2024

Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has released its financial results for the...

Company Deals

Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA:...

Company Medical Device

Siemens Healthineers AG Reports Fiscal 2024 Results with Targeted Revenue Growth

Fineline Cube Nov 7, 2024

Germany-based medical device giant Siemens Healthineers AG (ETR: SHL) has released its financial results for...

Company Drug

HutchMed to Present Updated Data from Solvleplenib ESLIM-01 Phase III Trial at ASH and ESMO Congress 2024

Fineline Cube Nov 7, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced plans to present new and...

Company Deals

Bayer HealthCare Partners with China Population Welfare Foundation at CIIE for Public Health Initiatives

Fineline Cube Nov 7, 2024

German pharmaceutical giant Bayer HealthCare (FRA: BAYN) has entered into a partnership agreement with the...

Company Deals

Medtronic Partners with China Resources Guangdong Pharmaceutical at CIIE for Medical Equipment Development

Fineline Cube Nov 7, 2024

US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong...

Company Drug

Pfizer’s Talzenna (talazoparib) Approved by China’s NMPA for mCRPC Treatment

Fineline Cube Nov 7, 2024

The National Medical Products Administration (NMPA) website has indicated that Pfizer’s (NYSE: PFE) marketing filing...

Company Drug

Shouyao Holdings Adjusts Development Strategy for SY-1530, Halts Monotherapy Clinical Trials

Fineline Cube Nov 7, 2024

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced a strategic adjustment regarding its...

Company Drug

Nanjing Leads Biolabs Secures FDA Orphan Drug Designation for LBL-034 in Multiple Myeloma Treatment

Fineline Cube Nov 7, 2024

Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced that it has received...

Company Drug

Sanofi’s Dupixent Gains EMA Approval for Eosinophilic Esophagitis in Children

Fineline Cube Nov 7, 2024

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...

Company Deals

Novartis Forges Partnerships at CIIE to Strengthen Radioligand Therapy Ecosystem in China

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), Swiss pharmaceutical giant Novartis (NYSE: NVS) announced...

Drug Medical Device Policy / Regulatory

China’s NHC Announces Initiative to Boost Gerontology Medical Services

Fineline Cube Nov 7, 2024

The National Health Commission (NHC) has issued a notification aimed at enhancing gerontology medical service...

Company Deals

Vantive Secures Collaborations with Kertone and Qiantang Longyue at CIIE for Dialysis Solutions

Fineline Cube Nov 7, 2024

Vantive, a planned spin-off from U.S.-based Baxter International (NYSE: BAX) specializing in kidney care, has...

Company Drug

Amgen’s Tavneos Receives NMPA Approval for ANCA-Associated Vasculitis Treatment in China

Fineline Cube Nov 7, 2024

US biotechnology company Amgen (NASDAQ: AMGN) has announced that it has received market approval in...

Company Medical Device

Boston Scientific Launches Vercisie Genius DBS System in China for Parkinson’s Disease Treatment

Fineline Cube Nov 7, 2024

US major Boston Scientific Corporation (NYSE: BSX) has officially launched its Vercisie Genius, an implantable...

Company Drug

CARSgen Therapeutics Presents Latest CAR-T Data at ASH Annual Meeting

Fineline Cube Nov 6, 2024

CARSgen Therapeutics Holdings Ltd (HKG: 2171), a China-based specialist in chimeric antigen receptor (CAR)-T cell...

Company Drug

Changchun High & New Technology Industries Receives NMPA Approval for Long-Acting Somatropin

Fineline Cube Nov 6, 2024

Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading China-based company, has...

Posts pagination

1 … 310 311 312 … 705

Recent updates

  • Hengrui Pharmaceuticals Secures Third NMPA Approval for Trastuzumab Rezetecan in HER2-Positive Colorectal Cancer
  • Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline
  • TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations
  • Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children
  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures Third NMPA Approval for Trastuzumab Rezetecan in HER2-Positive Colorectal Cancer

Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Company Drug

TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations

Others

Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.